Skip to main content

Table 1 Demographic and clinical data of the 125 patients of the intention-to-treat population and of the 96 patients of the per-protocol population at the time of randomization

From: A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine

 

ITT (n = 125)

PP (n = 96)

Age (years, mean ± SD)

37 ± 9

37 ± 9

Females (n, %)

99 (79)

75 (78)

Height (cm, mean ± SD)

167 ± 9

167 ± 9

Weight (kg, mean ± SD)

64 ± 13

64 ± 13

Age at onset of migraine (years, mean ± SD)

16 ± 7

16 ± 7

Migraine attack duration >2 days (n, %)

26 (21)

14 (15)

MIDAS score (mean ± SD)

22 ± 15

21 ± 16

Migraine with aura (n, %)

4 (3)

3 (3)

  1. Data are shown as mean (±SD), or absolute (n) and relative frequency (%)